HAS ASSESSMENT OUTCOMES | FRANCE PHARMA NEWS

HAS says OK to continue the reimbursement of Zykadia (ceritinib) for ALK + NSCLC

HAS gave a positive opinion to continue the reimbursement of Zykadia (ceritinib) for patients with ALK-positive non-small-cell lung cancer. The drug is reimbursed for patients who were previously treated with crizotinib.



Also read: Denmark Healthcare System




Crizotinib is the first product approved for ALK-positive NSCLC, which demonstrated the superiority over chemotherapy.

Alecensa (alectinib) had demonstrated superiority in progression-free survival and the risk of brain progression over crizotinib; it is the preferred treatment option for the first-line treatment of ALK+ lung cancer.

HAS has recommended Zyadia as a second-line treatment option after failure of first treatment (preferentially alectinib).


Zyadia received ASMR V considering the gain in progression-free survival versus chemotherapy. However, HAS believed that the trial result does not reflect the current treatment strategy.

The product has achieved SMR ‘Important.’

0 comments

Please donate to support iPharmaCenter. Click on donate button in header to support us. Thank you

©2020 by ipharmaservices